Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chimerix Crashes On Ph III Brincidofovir Flop; Dead End?

This article was originally published in Scrip

Executive Summary

Shares of Chimerix Inc. crashed on Dec. 28 – plummeting as low as 82% – on word the firm's Phase III SUPPRESS trial of its oral antiviral brincidofovir failed to achieve its primary endpoint of preventing clinically significant cytomegalovirus (CMV) infection in patients through week 24 after undergoing hematopoietic cell transplantation (HCT).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064081

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel